JP2014529606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014529606A5 JP2014529606A5 JP2014527112A JP2014527112A JP2014529606A5 JP 2014529606 A5 JP2014529606 A5 JP 2014529606A5 JP 2014527112 A JP2014527112 A JP 2014527112A JP 2014527112 A JP2014527112 A JP 2014527112A JP 2014529606 A5 JP2014529606 A5 JP 2014529606A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- compound
- antithrombin iii
- thrombin
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004411 Antithrombin III Human genes 0.000 claims 14
- 108090000935 Antithrombin III Proteins 0.000 claims 14
- 229960005348 antithrombin iii Drugs 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 108090000190 Thrombin Proteins 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229960004072 thrombin Drugs 0.000 claims 11
- 108010074860 Factor Xa Proteins 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 8
- 208000032843 Hemorrhage Diseases 0.000 claims 6
- 208000034158 bleeding Diseases 0.000 claims 6
- 230000000740 bleeding effect Effects 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 208000031169 hemorrhagic disease Diseases 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000003593 chromogenic compound Substances 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108010048049 Factor IXa Proteins 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527140P | 2011-08-25 | 2011-08-25 | |
| US61/527,140 | 2011-08-25 | ||
| PCT/NL2012/050581 WO2013028070A2 (en) | 2011-08-25 | 2012-08-24 | Compounds for use in boosting coagulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083956A Division JP2017186340A (ja) | 2011-08-25 | 2017-04-20 | 血液凝固促進に使用するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014529606A JP2014529606A (ja) | 2014-11-13 |
| JP2014529606A5 true JP2014529606A5 (enExample) | 2015-10-08 |
| JP6198277B2 JP6198277B2 (ja) | 2017-09-20 |
Family
ID=46845975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527112A Expired - Fee Related JP6198277B2 (ja) | 2011-08-25 | 2012-08-24 | 血液凝固促進に使用するための化合物 |
| JP2017083956A Pending JP2017186340A (ja) | 2011-08-25 | 2017-04-20 | 血液凝固促進に使用するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083956A Pending JP2017186340A (ja) | 2011-08-25 | 2017-04-20 | 血液凝固促進に使用するための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140356377A1 (enExample) |
| EP (1) | EP2747776B1 (enExample) |
| JP (2) | JP6198277B2 (enExample) |
| CN (1) | CN103930129A (enExample) |
| AU (1) | AU2012299524B2 (enExample) |
| BR (1) | BR112014004297B1 (enExample) |
| CA (1) | CA2846494C (enExample) |
| CY (1) | CY1120688T1 (enExample) |
| DK (1) | DK2747776T3 (enExample) |
| ES (1) | ES2689776T3 (enExample) |
| HU (1) | HUE039590T2 (enExample) |
| PL (1) | PL2747776T3 (enExample) |
| PT (1) | PT2747776T (enExample) |
| WO (1) | WO2013028070A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016519081A (ja) | 2013-03-14 | 2016-06-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体 |
| WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| WO2017100236A1 (en) | 2015-12-07 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| WO2017158176A1 (en) * | 2016-03-18 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-antithrombin single-domain antibodies and polypeptides comprising thereof |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CA3123177A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
| JP6883899B1 (ja) * | 2020-12-07 | 2021-06-09 | 株式会社血栓トランスレーショナルリサーチラボ | 血液凝固検査試薬、および血液凝固検査方法 |
| PL440675A1 (pl) * | 2022-03-17 | 2023-09-18 | Politechnika Wrocławska | Związki do równoległego wykrywania i hamowania proteaz szlaku krzepnięcia - APC, trombiny, czynnika Xa i czynnika XIa w ludzkim osoczu |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US748913A (en) * | 1904-01-05 | Fo model | ||
| ATE539764T1 (de) * | 2007-07-20 | 2012-01-15 | Univ Paris Sud Xi | Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen |
| DE102011081871A1 (de) * | 2011-08-31 | 2013-02-28 | Henkel Ag & Co. Kgaa | Oxazolidine zur Fehlgeruchsbekämpfung |
-
2012
- 2012-02-24 US US14/240,903 patent/US20140356377A1/en not_active Abandoned
- 2012-08-24 JP JP2014527112A patent/JP6198277B2/ja not_active Expired - Fee Related
- 2012-08-24 CA CA2846494A patent/CA2846494C/en active Active
- 2012-08-24 EP EP12758914.1A patent/EP2747776B1/en active Active
- 2012-08-24 BR BR112014004297-7A patent/BR112014004297B1/pt not_active IP Right Cessation
- 2012-08-24 CN CN201280052327.2A patent/CN103930129A/zh active Pending
- 2012-08-24 ES ES12758914.1T patent/ES2689776T3/es active Active
- 2012-08-24 DK DK12758914.1T patent/DK2747776T3/en active
- 2012-08-24 WO PCT/NL2012/050581 patent/WO2013028070A2/en not_active Ceased
- 2012-08-24 HU HUE12758914A patent/HUE039590T2/hu unknown
- 2012-08-24 PL PL12758914T patent/PL2747776T3/pl unknown
- 2012-08-24 PT PT12758914T patent/PT2747776T/pt unknown
- 2012-08-24 AU AU2012299524A patent/AU2012299524B2/en not_active Ceased
-
2017
- 2017-04-20 JP JP2017083956A patent/JP2017186340A/ja active Pending
-
2018
- 2018-09-19 CY CY181100967T patent/CY1120688T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014529606A5 (enExample) | ||
| de Abajo | Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients | |
| Schneider et al. | Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor | |
| JP2015517305A5 (enExample) | ||
| Hoffman et al. | The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review | |
| Ansari et al. | Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease | |
| AU2012299524B2 (en) | Compounds for use in boosting coagulation | |
| Miesbach et al. | Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study | |
| Leentjens et al. | A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents | |
| Park et al. | Factor V deficiency in Korean patients: clinical and laboratory features, treatment, and outcome | |
| Mikhail et al. | von Willebrand disease in the pediatric and adolescent population | |
| RU2013120033A (ru) | Фактор ii и фибриноген для лечения гемостатических нарушений | |
| CN115916165A (zh) | 用于治疗病毒性呼吸道感染的抗雄激素或雄激素受体拮抗剂 | |
| Tagliaferri et al. | Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers | |
| Barg et al. | An extra X does not prevent acquired hemophilia–pregnancy-associated acquired hemophilia A | |
| Passarelli et al. | Management of single uncomplicated dental extractions and postoperative bleeding evaluation in patients with factor V deficiency: a local antihemorrhagic approach | |
| Di Minno | Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders | |
| Ma et al. | Neuroprotective effects of long noncoding RNAs involved in ischemic postconditioning after ischemic stroke | |
| Zhang et al. | The Role of MCPIP1 in Macrophage Polarization and Cardiac Function Post‐Myocardial Infarction | |
| Yapijakis et al. | Common gene polymorphisms associated with thrombophilia | |
| Bassas et al. | Anticoagulation and antiplatelet therapy in dermatology | |
| Majluf-Cruz et al. | Long-term follow up analysis of nadroparin for hereditary angioedema. A preliminary report | |
| Hagel et al. | Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab | |
| Hsiao et al. | Drug-induced disorders and dental implant treatment | |
| Cacciola et al. | Effect of Anagrelide on Platelet Coagulant Function in Patients with Essential Thrombocythemia. |